Showing results (1-10 of 65) with videos related to

Sort By:
Pageof 7
Recent Patents on Anti-Cancer Drug Discovery|April 19, 2016
HER3 and its Ligand, Heregulin, as Targets for Cancer TherapyHisato Kawakami, Kimio Yonesaka
BMJ Case Reports|March 15, 2014
Successful gefitinib treatment administration via gastrostomy tube in a patient with non-small cell lung cancer with dysphagiaTomohiro Suzumura, Kimio Yonesaka, Hiroshi Tsukuda, et al.
Oncology Reports|November 29, 2018
Dual blockade of EGFR tyrosine kinase using osimertinib and afatinib eradicates EGFR‑mutant Ba/F3 cellsKimio Yonesaka, Yoshihisa Kobayashi, Hidetoshi Hayashi, et al.
International Journal of Cancer|August 19, 2005
Small interfering RNA targeting survivin sensitizes lung cancer cell with mutant p53 to adriamycinKimio Yonesaka, Kenji Tamura, Takayasu Kurata, et al.
Cancer Letters|September 9, 2006
Down-regulation of survivin by ultraviolet C radiation is dependent on p53 and results in G(2)-M arrest in A549 cellsMasato Ikeda, Isamu Okamoto, Kenji Tamura, et al.
Anticancer Research|September 10, 2014
Erlotinib is a well-tolerated alternate treatment for non-small cell lung cancer in cases of gefitinib-induced hepatotoxicityKimio Yonesaka, Tomohiro Suzumura, Hiroshi Tsukuda, et al.
Lung Cancer (Amsterdam, Netherlands)|February 27, 2017
Circulating heregulin level is associated with the efficacy of patritumab combined with erlotinib in patients with non-small cell lung cancerKimio Yonesaka, Kenji Hirotani, Joachim von Pawel, et al.
Pageof 7